Revised Response Criteria for Malignant Lymphoma

Overview

Journal J Clin Oncol

Specialty Oncology

Date 2007 Jan 24

PMID 17242396

Citations 1704

Authors

Bruce D Cheson

Beate Pfistner

Malik E Juweid

Randy D Gascoyne

Lena Specht

Sandra J Horning

Bertrand Coiffier

Richard I Fisher

Anton Hagenbeek

Emanuele Zucca

Steven T Rosen

Sigrid Stroobants

T Andrew Lister

Richard T Hoppe

Martin Dreyling

Kensei Tobinai

Julie M Vose

Joseph M Connors

Massimo Federico

Volker Diehl

Affiliations

Soon will be listed here.

Abstract

Purpose: Standardized response criteria are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies.

Methods: The International Working Group response criteria (Cheson et al, J Clin Oncol 17:1244, 1999) were widely adopted, but required reassessment because of identified limitations and the increased use of [18F]fluorodeoxyglucose-positron emission tomography (PET), immunohistochemistry (IHC), and flow cytometry. The International Harmonization Project was convened to provide updated recommendations.

Results: New guidelines are presented incorporating PET, IHC, and flow cytometry for definitions of response in non-Hodgkin's and Hodgkin's lymphoma. Standardized definitions of end points are provided.

Conclusion: We hope that these guidelines will be adopted widely by study groups, pharmaceutical and biotechnology companies, and regulatory agencies to facilitate the development of new and more effective therapies to improve the outcome of patients with lymphoma.

Citing Articles

Day 100 Absolute Monocyte/Lymphocyte Prognostic Score and Survival Post Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation in Diffuse Large B-Cell Lymphoma.

Velazquez A, Inwards D, Ansell S, Micallef I, Johnston P, Hogan W J Cancer Ther. 2025; 4(8):1298-1305.

PMID: 40051827 PMC: 11884249. DOI: 10.4236/jct.2013.48153.

Obesity and overweight in R/R DLBCL patients is associated with a better response to treatment of R2-GDP-GOTEL trial. Potential role of NK CD8 + cells and vitamin D.

Hontecillas-Prieto L, Garcia-Dominguez D, Jimenez-Cortegana C, Nogales-Fernandez E, Palazon-Carrion N, Garcia-Sancho A Cancer Metab. 2025; 13(1):12.

PMID: 40038834 PMC: 11881355. DOI: 10.1186/s40170-025-00381-7.

Further strategies after immune checkpoint inhibitors in relapsed/refractory Hodgkin lymphoma: salvage treatments and consolidation with transplantation, experience in daily clinical practice.

Pellegrini C, Casadei B, Broccoli A, Cantelli M, Gugliotta G, Gentilini M Ann Hematol. 2025; .

PMID: 40025210 DOI: 10.1007/s00277-025-06255-8.

Improved prognosis of advanced-stage extranodal NK/T-cell lymphoma: results of the NKEA-Next study.

Fujimoto A, Miyazaki K, Yakushijin K, Fujino T, Munakata W, Ejima Y Leukemia. 2025; .

PMID: 39962328 DOI: 10.1038/s41375-025-02527-4.

Canine Multicentric Lymphoma: Diagnostic, Treatment, and Prognostic Insights.

Rocha M, Araujo D, Carvalho F, Vale N, Pazzini J, Feliciano M Animals (Basel). 2025; 15(3).

PMID: 39943162 PMC: 11816192. DOI: 10.3390/ani15030391.